08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

MediciNova, University of Colorado deal

The university granted MediciNova exclusive, U.S. rights to ibudilast ( AV411 , MN166) to treat post-traumatic brain injury (TBI). The glial cell regulator that suppresses IL-1 beta, tumor necrosis factor (TNF) alpha and IL-6 is...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Adeona management update

Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann Arbor, Mich.   Business: Autoimmune   Hired: John Monahan as SVP of R&D, founder and formerly CEO of Avigen Inc. , which MediciNova Inc. acquired  ...
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

Ibudilast: Phase II start

In October, MediciNova said investigators will begin a double-blind, placebo-controlled, Australian Phase II trial to evaluate twice-daily oral ibudilast for 8 weeks in about 40 patients. MediciNova gained rights to ibudilast to treat neuropathic pain...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

Ibudilast: Preliminary Phase Ib/IIa data

Preliminary data from a double-blind, U.S. Phase Ib/IIa trial in 30 heroin-dependent patients showed that twice-daily 40 mg ibudilast met the primary endpoint of significantly reducing average SOWS scores from baseline vs. placebo (p<=0.05). Twice-daily...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

Ibudilast: Phase Ib started

MediciNova began a double-blind, placebo-controlled, crossover, U.S. Phase Ib trial to evaluate twice-daily 20 and 50 mg oral ibudilast for 7 days in 12 methamphetamine-dependent patients. MediciNova gained rights to ibudilast to treat neuropathic pain...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

MediciNova management update

MediciNova Inc. (NASDAQ:MNOV; Osaka:4875), San Diego, Calif.   Business: Genitourinary, Inflammation, Neurology   Hired: Kirk Johnson as CSO, formerly VP of R&D at Avigen Inc. ; MediciNova acquired Avigen last December (see BioCentury, Dec. 21,...
08:00 , Feb 8, 2010 |  BioCentury  |  Product Development

Checking the boxes in gene therapy

Amsterdam Molecular Therapeutics thinks its Glybera represents the right combination of vector, gene and disease setting to become the first gene therapy to be approved outside of China. The European Medicines Agency now has accepted...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Avigen, MediciNova deal

MediciNova completed its previously announced acquisition of Avigen after shareholders of both companies approved the deal (see BioCentury, Aug. 24). Avigen Inc. (NASDAQ:AVGN), Alameda, Calif.   MediciNova Inc. (NASDAQ:MNOV; Osaka:4875), San Diego, Calif.   Business:...
08:00 , Dec 21, 2009 |  BioCentury  |  Finance

Ebb & Flow

The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc . (Tokyo:4503) has led to big payoffs in the last two weeks for Calixa Therapeutics Inc. and...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Company News

Adamas Pharmaceuticals management update

Adamas Pharmaceuticals Inc. , Emeryville, Calif.   Business: Neurology, Infectious   Hired: Michael Coffee as SVP of sales and marketing; formerly CBO for Avigen Inc.  ...